Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial.

Saved in:
Bibliographic Details
Title: Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial.
Authors: Bonnefoi H; Department of Medical Oncology, Institut Bergonié, INSERM U1312 BRIC, Université de Bordeaux Collège Sciences de la Santé, Bordeaux, France. Electronic address: h.bonnefoi@bordeaux.unicancer.fr., Lerebours F; Department of Medical Oncology, Institut Curie, St Cloud, France., Pulido M; Clinical and Epidemiological Research Unit, Institut Bergonié, INSERM CIC1401, Bordeaux, France., Arnedos M; Department of Medical Oncology, Institut Bergonié, INSERM U1312 BRIC, Bordeaux, France., Tredan O; Department of Medical Oncology, Centre Léon Bérard, Cancer Research Center of Lyon (UMR Inserm 1052 - CNRS 5286), Lyon, France., Dalenc F; Department of Medical Oncology, Oncopole Claudius Regaud, IUCT-Oncopole, Université de Toulouse, Toulouse, France., Guiu S; Department of Medical Oncology, Institut du Cancer Montpellier - Val d'Aurelle Montpellier, France., Teixeira L; Department of Senologie, Hôpital Saint Louis, INSERM U976, Université Paris Cité, Paris, France., Mollon D; Department of Medical Oncology, Centre Hospitalier de Cornouaille, Quimper, France., Levy C; Department of Medical Oncology, Centre François Baclesse, Caen, France., Verret B; Department of Medical Oncology, Gustave Roussy, Villejuif, France., Dawood H; Department of Medical Oncology, Centre Hospitalier Régional, Orléans, France., Deiana L; Department of Medical Oncology, Centre Hospitalier Universitaire, Brest, France., Mouret Reynier MA; Department of Medical Oncology Centre Jean Perrin, Clermont Ferrand, France., Augereau P; Department of Medical Oncology, Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France., Canon JL; Department of Medical Oncology, Grand Hôpital de Charleroi, Charleroi, Belgium., Huchet N; Clinical and Epidemiological Research Unit, Institut Bergonié, Bordeaux, France., Guyonneau C; R&D Department, UNICANCER, Paris, France., Lemonnier J; R&D Department, UNICANCER, Paris, France., MacGrogan G; Department of Pathology, Institut Bergonié, Bordeaux, France., Gonçalves A; Department of Medical Oncology, Institut Paoli-Calmettes, INSERM, CNRS, CRCM, Aix Marseille Univ, Marseille, France., Darbo E; INSERM U1312, Université de Bordeaux, Bordeaux, France., Iggo R; INSERM U1312, Department of Medical and Biological Sciences, Université de Bordeaux, Bordeaux, France.
Source: The Lancet. Oncology [Lancet Oncol] 2025 Mar; Vol. 26 (3), pp. 355-366. Date of Electronic Publication: 2025 Feb 17.
Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study; Randomized Controlled Trial
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-5488
DOI:10.1016/S1470-2045(24)00737-X